Today marks an important milestone in our mission to transform diabetes care. I am excited to share that Glooko has acquired Monarch Medical Technologies, creators of the EndoTool® Glucose Management System.
With this acquisition, Glooko is positioned to become the only diabetes management company with the potential to connect the full continuum of care — from home to hospital and back again. By bringing together EndoTool’s proven inpatient insulin dosing technology with Glooko’s leading outpatient platform, we aim to create a future where care is seamless, safer, and more supportive for both people living with diabetes and healthcare providers.
For patients, this means fewer disruptions as they move between settings, reduced risk of dangerous glycemic events, and more confidence that their care is connected. For healthcare providers, it means access to tools that simplify complex insulin management, standardize protocols, and free up time to focus on what matters most, which is caring for people.
This step also sets the foundation for Glooko’s future: using data and AI to help clinicians anticipate risks earlier, personalize care at scale, and improve outcomes under value-based models. By aligning advanced technology with clinical guidelines and EHR workflows, we can help hospitals and health systems deliver higher-quality care while lowering costs.
Our mission has always been clear: to simplify diabetes management, strengthen connections across the care team, and improve lives. This acquisition represents an important stride toward that vision.
Together, we are building a future where diabetes care is more connected, proactive, and patient-centered than ever.
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions.